Elicitation of predictable immune responses by using live bacterial vectors

被引:25
作者
Drabner, B [1 ]
Guzmán, CA [1 ]
机构
[1] GBF German Res Ctr Biotechnol, Div Microbiol, Vaccine Res Grp, D-38124 Braunschweig, Germany
来源
BIOMOLECULAR ENGINEERING | 2001年 / 17卷 / 03期
关键词
attenuated bacteria; carriers; DNA vaccines; mucosal immunity; vaccines;
D O I
10.1016/S1389-0344(00)00072-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
There is an increasing need for novel vaccines able to stimulate efficient and long-lasting responses, which have also low production costs. To confer protective immunity following vaccination, the adequate type of response should be elicited. Vaccines based on attenuated bacterial carriers have contained production and delivery costs, and are able to stimulate more potent immune responses than non-replicating formulations. The improved knowledge on carrier physiology and host response, the availability of different mutants and highly sophisticated expression tools, and the possibility of co-administering modulators enable to trigger predictable responses according to the specific needs. Recent studies support the use of attenuated bacteria nut only as conventional carriers, but also as a delivery system for DNA vaccines against infectious agents and tumors. In this review we discuss the most widely used bacterial carrier systems for either antigens or nucleic acid vaccines, and the strategies which have been successfully exploited to modulate the immune responses elicited. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 102 条
[1]   HUMORAL AND CELL-MEDIATED IMMUNE-RESPONSES TO LIVE RECOMBINANT BCG-HIV VACCINES [J].
ALDOVINI, A ;
YOUNG, RA .
NATURE, 1991, 351 (6326) :479-482
[2]   Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: Expression levels and immune response [J].
Anderson, R ;
Dougan, G ;
Roberts, M .
VACCINE, 1996, 14 (14) :1384-1390
[3]   RECOMBINANT BCG AS A CANDIDATE ORAL VACCINE VECTOR [J].
BARLETTA, RG ;
SNAPPER, B ;
CIRILLO, JD ;
CONNELL, ND ;
KIM, DD ;
JACOBS, WR ;
BLOOM, BR .
RESEARCH IN MICROBIOLOGY, 1990, 141 (7-8) :931-939
[4]  
Bârzu S, 1998, INFECT IMMUN, V66, P77
[5]   Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni [J].
Ben-Yedidia, T ;
Tarrab-Hazdai, R ;
Schechtman, D ;
Arnon, R .
INFECTION AND IMMUNITY, 1999, 67 (09) :4360-4366
[6]  
BLACK R, 1982, DEV BIOLOGICALS, V53, P9
[7]  
Boland A, 2000, Subcell Biochem, V33, P343
[8]   Transgene as vaccine for chlamydia [J].
Brunham, RC ;
Zhang, DJ .
AMERICAN HEART JOURNAL, 1999, 138 (05) :S519-S522
[9]   USE OF THE NIRB PROMOTER TO DIRECT THE STABLE EXPRESSION OF HETEROLOGOUS ANTIGENS IN SALMONELLA ORAL VACCINE STRAINS - DEVELOPMENT OF A SINGLE-DOSE ORAL TETANUS VACCINE [J].
CHATFIELD, SN ;
CHARLES, IG ;
MAKOFF, AJ ;
OXER, MD ;
DOUGAN, G ;
PICKARD, D ;
SLATER, D ;
FAIRWEATHER, NF .
BIO-TECHNOLOGY, 1992, 10 (08) :888-892
[10]   BACTERIAL VACCINE VECTORS AND BACILLUS-CALMETTE-GUERIN [J].
CIRILLO, JD ;
STOVER, CK ;
BLOOM, BR ;
JACOBS, WR ;
BARLETTA, RG .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (04) :1001-1009